Blog

Business analysis cost comparison, Taxes payment, Businessman use Laptop and calculator for bookkeeping payroll and budget tax, Growth with financial graph, document finance accounting investment

Valuation multiples for European MedTech companies in mid-2025 are being driven by a combination of key macroeconomic, technological, and strategic factors. While there's been a degree of caution in the broader market, high-quality assets are commanding premiums, and a clear flight to quality is evident.Here's a breakdown of the primary drivers:1. The Dominance of Artificial Intelligence (AI) and Digital Health AI is the single biggest driver of valuation premiums in the European health tech sector. Companies with a strong AI component are valued significantly higher than their traditional counterparts.&nbsp;Proprietary AI and Data Platforms: Firms that have developed proprietary AI algorithms for diagnostics, drug discovery, or patient care are seeing heightened interest. This technology is seen as a key to future revenue potential and a strong competitive moat.Clinically Validated Solutions: Investors are moving beyond the hype. They are paying a premium for companies that can demonstrate tangible, real-world clinical validation of their AI solutions through studies, pilot programs, or partnerships.Integration and "Workflow Lock-in": AI solutions that are deeply integrated into existing clinical workflows, such as Electronic Health Records (EHRs) or imaging systems, are highly valued. This "sticky" nature of the product creates high switching costs and ensures sustained revenue.Focus on High-Impact Areas: Investment is becoming more selective, concentrating on areas where AI can have an immediate and significant impact, such as diagnostics (e.g., medical imaging analysis), drug discovery, and physician support tools.&nbsp;2. A Maturing Regulatory and Investment Environment The European regulatory landscape is providing more clarity, which is boosting investor confidence.EU AI Act: The implementation of the EU AI Act is providing a much-needed framework for the safe and ethical use of AI in healthcare, which reduces risk for both developers and investors.European Health Data Space (EHDS): Initiatives like the EHDS are designed to facilitate the secure exchange of health data across the EU. This is a game-changer for AI development, as it provides the foundation for training more robust AI models, attracting more investment. Renewed Investor Interest: After a period of caution, capital is flowing back into the European digital health sector. Private equity firms and venture capital funds are actively seeking out high-quality AI companies, which is increasing competition and pushing up valuations.3. Favourable Economic and Demographic TrendsBroader market conditions and long-term demographic shifts are making the MedTech sector particularly attractive.Aging Population and Chronic Disease Management: Europe's aging population is creating a rising demand for solutions that can manage chronic conditions and improve long-term care. MedTech companies that address these needs are seen as having a strong, stable, and growing market.Value-Based Care: The shift from a "fee-for-service" to a "value-based care" model is accelerating. Solutions that can demonstrate measurable cost savings and improved patient outcomes are especially attractive to buyers.Consolidation and M&amp;A Activity: The European MedTech market is highly fragmented. Larger players are actively acquiring smaller, innovative firms to consolidate market share, achieve economies of scale, and broaden their portfolios. This "string-of-pearls" M&amp;A strategy by biopharma and large MedTech companies is a key driver of deal volume and valuation.4. Valuation Metrics and Multiples Based on recent market reports, here are some general valuation benchmarks:Average Revenue Multiples (EV/Revenue): For general HealthTech companies, the average revenue multiple is in the range of 4x-6x.Premium for AI/Digital Health: Companies with proprietary AI solutions, telehealth platforms, or advanced analytics can command significantly higher multiples, potentially ranging from 6x-8x revenue, or even higher in select cases.Average EBITDA Multiples (EV/EBITDA): For MedTech companies with positive earnings, the multiples are generally observed between 10x-14x, a slight increase from 2024, reflecting cautious optimism and a focus on profitability.&nbsp;In summary, while the overall M&amp;A market has been selective, the European MedTech sector is proving resilient.Valuations are being driven by a clear preference for companies that leverage AI to deliver clinically proven, cost-effective, and scalable solutions that address fundamental demographic and systemic healthcare challenges.To discuss how Nelson Advisors can help your MedTech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

What is driving MedTech valuation multiples in Europe mid 2025?

The European MedTech Specialist &nbsp; Nelson Advisors is a highly specialised advisory firm with a singular focus on the healthcare technology sector. It is precisely defined as a mergers and acquisitions, partnerships and investment advisory firm that operates within the dynamic and rapidly evolving HealthTech landscape. This exclusive dedication to a specific industry is the bedrock of the firm's value proposition, providing a nuanced understanding of the unique market dynamics and technological advancements that are essential for successful transactions in this complex field. &nbsp;&nbsp; The firm's primary physical presence is in London, UK, positioning it strategically within the European HealthTech hub. While its physical headquarters are in Europe, its geographic scope is deliberately broad, catering to a client base that spans the UK, Europe, and North America. The international capabilities of its partners are extensive, with corporate finance experience and transaction exposure across numerous countries, including the US, Ireland, Sweden, Denmark, Switzerland, Germany, Austria, Italy, Poland, Ukraine, Russia, Kazakhstan, Hong Kong, Singapore, and Australia. This international reach allows the firm to facilitate complex, cross-border transactions that are increasingly common in the global HealthTech market. &nbsp;Exclusive Specialisation in the MedTech Ecosystem &nbsp;&nbsp; The core of Nelson Advisors' business model is its deep and exclusive specialisation in the HealthTech sector. This focus is a significant competitive advantage over generalist firms, enabling the firm to develop a sophisticated understanding of the industry's complex dynamics. The firm’s expertise extends across a diverse range of sub-sectors, which demonstrates a comprehensive grasp of the entire HealthTech ecosystem. &nbsp;&nbsp; The firm’s specialised sub-segments include: MedTech: Encompasses the use of technology, products, services and solutions to diagnose, prevent, monitor, treat, and alleviate diseases and health conditions. It is a critical component of modern healthcare, enabling medical professionals to provide more accurate, efficient, and effective care.HealthTech: The firm’s focus here is on fundamental technological innovations in healthcare, such as advanced medical devices, robotics, bioprinting, and nanotechnology. These are often associated with early-stage companies and startups developing novel solutions to healthcare challenges.Digital Health: This area covers a broad range of technology-driven solutions, including mobile health apps, telehealth platforms, wearable devices, and personalized wellness solutions.Health IT: This specialisation centres on the technology used to manage, store, and share health information, including systems like electronic health records (EHRs) and clinical decision support tools.Consumer Health: The firm advises companies that provide solutions directly to the end user, including AI-driven diagnostics and digital biomarkers.Healthcare Cybersecurity: This is a crucial area of specialisation dedicated to ensuring the confidentiality, integrity, and availability of sensitive healthcare information and systems. The firm's focus on this segment is a direct response to the sensitive nature of patient data and the increasing sophistication of cyber threats.Healthcare AI: This sub-sector leverages AI techniques like machine learning and natural language processing to analyse complex medical data, provide insights, and enhance operational efficiency. &nbsp;&nbsp; The firm's explicit inclusion of Healthcare AI and Cybersecurity is not just a listing of services but a strategic signal of long-term foresight. The partners understand that these specific, complex, and high-growth areas will be central to future value creation and risk management in HealthTech. The firm's proactive specialisation in these sub-sectors, which are subject to emerging regulations like the EU AI Act and the European Health Data Space (EHDS), distinguishes them from firms with a more general HealthTech focus. This expertise is invaluable for clients who need to navigate advanced technological landscapes and stringent regulatory environments. &nbsp;&nbsp; Comprehensive M&amp;A and Advisory Services &nbsp;&nbsp; Nelson Advisors offers a comprehensive suite of advisory services that are meticulously tailored to address the diverse needs of its clients. The firm provides a full range of M&amp;A services, including both buy-side and sell-side advisory. For companies seeking to divest, the firm guides them through the intricate sell-side process, which includes valuation, market positioning, negotiation, and deal closure, with the goal of securing optimal outcomes for the seller. On the buy-side, Nelson Advisors assists clients in identifying, evaluating, and ultimately acquiring suitable HealthTech companies that align with their strategic objectives and growth mandates. &nbsp;&nbsp; Beyond traditional M&amp;A, the firm's services extend to corporate divestitures, strategic partnerships, and portfolio optimization. The firm helps clients sell non-core assets or business units to liberate capital for reinvestment in higher-growth areas. The firm also provides investment-related advisory services, such as fundraising and commercial due diligence, demonstrating a role that goes beyond transactional execution to include strategic capital planning and partnership formation. A unique service offering is Tech Asset Sales, where the firm facilitates the sale of discrete technology assets, acknowledging the value of intellectual property and specific technological components that companies may wish to monetise or divest.To discuss how Nelson Advisors can help your HealthTech or MedTech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors: Boutique European MedTech Investment Banking specialising in M&A Advisory

Multicolored Pills scattered from white plastic medicine container

Eli Lilly is a major player in the field of GLP-1 agonists, a class of drugs that have revolutionized weight loss and diabetes management. While their injectable GLP-1 medications like Zepbound (tirzepatide) have seen significant success, the company is now at the forefront of a new wave of innovation: oral GLP-1 pills.Eli Lilly's Oral GLP-1: Orforglipron Eli Lilly's investigational oral GLP-1 drug is called orforglipron. It is a once-daily, non-peptide small molecule that acts as a GLP-1 receptor agonist. This is a significant innovation because, unlike other GLP-1s, orforglipron is not a peptide, which can be more difficult to formulate as a pill due to digestion. Its small molecule structure allows it to be taken orally without restrictions on food and water.Recent Phase 3 clinical trial results have been very promising for orforglipron:Weight Loss Efficacy: In trials for adults with obesity, orforglipron has shown clinically meaningful weight loss. In one pivotal trial, participants on the highest dose lost an average of 12.4% (27.3 lbs) of their body weight over 72 weeks.Cardiometabolic Benefits: Beyond weight loss, the drug has also shown improvements in cardiovascular risk factors, including non-HDL cholesterol, triglycerides, and systolic blood pressure. Safety Profile: The safety and tolerability profile of orforglipron has been consistent with that of injectable GLP-1 therapies, with the most common side effects being gastrointestinal-related. Regulatory Timeline: With the successful completion of Phase 3 trials, Eli Lilly is on track to submit orforglipron for regulatory approval to global agencies by the end of 2025. If approved, it could be available to patients by late 2026 or early 2027. The Future of GLP-1 Pills for Weight LossThe development of effective GLP-1 pills represents a major shift in the weight loss and obesity treatment landscape. Here's why this innovation is so significant and what it means for the future:Increased Accessibility and Patient Choice: A once-daily pill offers a more convenient and discreet alternative to weekly injections. This could be a game-changer for people with needle anxiety or for whom the injection format is a barrier to treatment. The pill format also simplifies storage and travel. Addressing Supply Constraints: The demand for injectable GLP-1s has often outpaced supply, leading to shortages. Eli Lilly has stated its confidence in its ability to manufacture and launch orforglipron "at scale," which could help alleviate some of these supply issues and make treatment more widely available. The Chronic Disease Model: GLP-1 drugs are increasingly being viewed as long-term therapies for a chronic disease. The convenience of a pill may encourage greater adherence to long-term treatment, helping patients sustain their weight loss and manage related health conditions. Expanding Indications: As research continues, GLP-1 drugs are showing promise for a range of health conditions beyond diabetes and weight loss, including cardiovascular disease, kidney disease, sleep apnea, and potentially even neurological conditions like Alzheimer's. The development of oral forms will likely accelerate this trend, as the convenience of a pill makes them more suitable for long-term use across a wider patient population. Competition and Continued Innovation: Eli Lilly is not the only company in the oral GLP-1 space. Other pharmaceutical companies are also developing similar drugs, which will drive further innovation and potentially lead to new formulations, greater efficacy, and improved side effect profiles. In summary, Eli Lilly's work on orforglipron highlights a critical leap in the field of weight loss medicine. By transitioning from injectables to a daily pill, the company is not only providing a more patient-friendly option but also helping to expand access, redefine the treatment of obesity as a chronic condition, and shape the future of medicine.To discuss how Nelson Advisors can help your HealthTech, MedTech or PharmaTech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

The Future of GLP-1 Pills for Weight Loss

Old woman in bed looking at screen of laptop and consulting with a doctor online at home, telehealth

Virtual wards, which gained significant traction during the COVID-19 pandemic, are a form of "hospital at home" care. They allow patients who would otherwise be in a physical hospital bed to receive acute care, remote monitoring, and treatment in their own homes. The next evolution of virtual wards will be driven by technological advancements and the need to address key challenges, moving from a reactive, crisis-management model to a proactive, holistic, and integrated part of the healthcare system.The Next Evolution: A Shift from Reactive to Proactive Care The next evolution of virtual wards will be defined by the following characteristics:1. Hyper-Personalisation and Predictive Analytics:What it is: Instead of a "one-size-fits-all" approach, virtual wards will use AI and machine learning to analyze a patient's real-time data from a combination of wearables, smart devices, and electronic health records. This will allow for the creation of highly personalised care plans.Why: This shift moves from simply monitoring vital signs to predicting potential health crises before they occur. For example, an AI algorithm could detect subtle changes in a patient's heart rate, oxygen levels, and activity patterns that signal a high risk of deterioration, allowing for a proactive intervention before a hospital admission becomes necessary.When: This is already in development and will become more widespread in the next 3-5 years. The foundational technology exists, but integration, regulatory approval, and clinician adoption are the key hurdles.2. A "Continuum of Care" Model:What it is: Virtual wards will no longer be a standalone service for acute episodes but will be seamlessly integrated into a patient's long-term care journey. This will involve smooth transitions between hospital, virtual ward, primary care, and community services.Why: Currently, many virtual wards are "step-up" (avoiding hospital admission) or "step-down" (facilitating early discharge). The next evolution will blur these lines, allowing for a continuous monitoring and support system for patients with chronic conditions like COPD or heart failure. This will reduce readmissions and improve overall health outcomes.&nbsp;When: This is a more complex evolution that requires systemic change. It will be a phased rollout over the next 5-10 years, depending on the ability of different healthcare providers to share data and coordinate care. 3. Enhanced Technology Integration and Interoperability:What it is: The next generation of virtual wards will feature a fully integrated technological ecosystem. This means seamless communication between different platforms, including:Internet of Medical Things (IoMT): A wider range of smart devices and sensors (e.g., smart scales, continuous glucose monitors, blood pressure cuffs) that automatically transmit data. Augmented Reality (AR) &amp; Virtual Reality (VR): AR could be used by clinicians during home visits to overlay a patient's real-time data onto a live view, or for remote consultations. VR could be used for patient education or physical therapy.EHR Integration: Real-time, two-way data sharing with a patient's Electronic Health Record (EHR) will be standard, providing a single source of truth for all healthcare providers.Why: Current systems often operate in silos, leading to fragmented data and communication breakdowns. True interoperability is essential to deliver the personalized, proactive care of the future. When: This is a continuous process. Significant progress is expected in the next 2-5 years as healthcare providers prioritize data integration and adopt national standards. 4. Expanding Clinical Applications:What it is: While initially focused on respiratory illnesses and frailty, virtual wards will expand to a much wider range of conditions. This includes acute mental health, pediatric care, post-surgical recovery, and even end-of-life care.Why: The success of virtual wards in managing a few key conditions has demonstrated the model's potential. As technology becomes more sophisticated and accepted, it will be applied to new clinical pathways where home-based care can improve patient experience and outcomes.When: This is already happening, with pilots for new conditions being launched. A significant expansion into new clinical areas is expected over the next 2-5 years. Key Drivers for the Evolution Growing demand and aging populations: Healthcare systems are under immense pressure. Virtual wards offer a scalable solution to the rising demand for hospital beds, especially for an aging population with multiple chronic conditions. Patient preference: A significant body of evidence shows that patients prefer to be cared for in the comfort of their own homes, which can also lead to better recovery outcomes.Economic incentives: Virtual wards can be a more cost-effective model of care than traditional inpatient stays, helping to free up hospital resources and reduce overall healthcare expenditure.Technological maturity: The technologies that enable virtual wards—from wearables to AI—are becoming more sophisticated, affordable, and user-friendly, making widespread adoption a reality.To discuss how Nelson Advisors can help your HealthTech or MedTech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Virtual Wards: what is the next evolution, why and when?

Orange neon glowing sine wave and a blue trigonometric curve reflected by mirrors in black background. Illustration of the concept of technology, science and mathematics

Electric medicine, a sub-sector of healthtech, is a rapidly growing field that uses electrical energy to treat diseases and conditions. This trend is attracting significant investment from venture capital firms and is driving strategic acquisitions within the medical technology (medtech) industry.&nbsp;⚡️ What is Electric Medicine? Electric medicine, also known as bioelectric medicine or electroceuticals, involves using electrical impulses to stimulate or block nerve signals to treat a variety of conditions. Instead of traditional pharmaceuticals, these treatments use devices that interface with the body's nervous system.Key applications include:Pain management: Devices like Transcutaneous Electrical Nerve Stimulation (TENS) units for chronic pain relief.Neurological disorders: Deep brain stimulators for conditions like Parkinson's disease and epilepsy.Cardiology: Implantable cardioverter-defibrillators (ICDs) and pacemakers for heart rhythm disorders.Mental health: Electroconvulsive therapy (ECT) and vagus nerve stimulation for severe depression.💰 Increasing Venture Capital Investment While overall venture capital funding in healthtech has experienced some fluctuations, investment in specific, high-growth areas like electric medicine and AI-driven solutions is surging. The market for bioelectric medicine was valued at over $21 billion in 2022 and is projected to reach over $35 billion by 2030. This growth is driven by the rising prevalence of chronic conditions and an aging population.Venture capitalists are drawn to electric medicine for several reasons:Proven Technology: Many of these devices, such as pacemakers, have long-standing clinical validation. Non-invasive Potential: The development of non-invasive electroceuticals is a particularly attractive area for investment.Regulatory Pathway: Unlike drug development, which can be a 10-15 year process, medical device development often has a more defined and potentially faster regulatory path.Value-based Care: These technologies align with the shift toward value-based care by offering solutions that can improve patient outcomes and reduce long-term healthcare costs. 🤝 Strategic Acquisitions The electric medicine trend is also fueling strategic acquisitions as larger medical device companies seek to expand their portfolios and stay competitive. Instead of focusing on incremental improvements to existing products, companies are acquiring smaller, innovative startups to gain access to new technologies and expand into high-growth markets.Recent strategic acquisitions in the medtech space include:Johnson &amp; Johnson's acquisition of Abiomed for its heart pump technology and Shockwave Medical for its cardiovascular devices. Stryker's acquisition of Inari Medical for its vascular clot removal solutions.Boston Scientific's acquisition of Relievant Medsystems for its pain management solutions and Axonics for its sacral neuromodulation systems.These acquisitions are driven by a need to integrate new technologies, strengthen product portfolios, and position companies as leaders in emerging fields like electrophysiology, neuromodulation, and vascular health. This M&amp;A activity is expected to continue as the market for electric medicine and related healthtech solutions expands.To discuss how Nelson Advisors can help your HealthTech or MedTech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Electric Medicine attracting investment and driving strategic acquisitions

Ambient voice technology, often referred to as ambient AI or AI scribes, is a rapidly evolving field with significant predicted growth for 2026. The technology is moving from being a simple dictation tool to an intelligent "co-pilot" that passively listens to conversations and automatically generates notes, reports, and other documentation. The predictions for 2026 are largely driven by a combination of technological advancements, market demand, and strategic initiatives, particularly within the healthcare sector.Key Predictions for 20261. Mainstream Adoption, Especially in Healthcare2026 is poised to be a pivotal year for the widespread adoption of ambient voice technology, particularly in healthcare settings. The administrative burden on clinicians is a major challenge, and AVT is seen as a key solution. Trials and pilot programs in organizations like the UK's NHS and various health systems in the US have shown significant benefits, including:Reduced Administrative Time: Clinicians can save a substantial amount of time—estimated at 10 to 15 minutes per patient encounter—by no longer needing to manually type notes. Improved Clinician Satisfaction: By alleviating burnout from paperwork, AVT allows doctors and nurses to focus more on patient care and less on administrative tasks. Enhanced Patient Experience: With clinicians making more eye contact and being more present, patient satisfaction is expected to increase. 2. Shift from Dictation to "True Ambient" FunctionalityCurrent AVT systems often require a voice prompt or a button press to start and stop recording. In 2026, the technology is expected to become more truly "ambient," operating passively in the background with advanced microphone arrays and AI to capture conversations without explicit activation. This will enable a more seamless and natural workflow.3. Integration and InteroperabilityThe push for seamless integration with existing systems, particularly Electronic Health Records (EHRs), will be a major trend. Vendors are focusing on creating solutions that can easily and securely transfer data, eliminating the need for clinicians to manually move information. This is critical for unlocking the full value of the technology.4. Advanced AI and Multilingual CapabilitiesThe underlying AI models, particularly Large Language Models (LLMs), will become more sophisticated. This will lead to:Higher Accuracy: Improved speech recognition will be able to handle diverse accents, dialects, and complex medical terminology with near-perfect accuracy. Multilingual Support: As healthcare systems serve diverse populations, AVT will need to offer robust multilingual capabilities, allowing for real-time translation and documentation in various languages. 5. Evolution of the Regulatory LandscapeAs AVT becomes more prevalent, the regulatory environment will continue to mature. In 2026, there will be an increased focus on:Clinical Safety: New regulations and guidelines will be established to ensure the technology does not introduce errors or "hallucinations" that could compromise patient care. Data Privacy and Security: The use of patient data for AI training and documentation will be subject to strict data protection laws, such as HIPAA in the US and GDPR in Europe. Growth Drivers and ChallengesGrowth Drivers:Demand for Productivity: Both the public and private sectors are under immense pressure to improve productivity and efficiency, making AVT a highly attractive investment. Government Initiatives: In places like the UK, government-led digital transformation plans are explicitly calling for the use of AI scribes, backed by significant funding. Technological Maturity: The rapid evolution of AI, particularly in natural language processing (NLP), has made ambient voice technology both accurate and scalable. Challenges:Cost and Implementation Hurdles: While the long-term benefits are clear, the initial cost of adoption and the complexity of integrating new technology into legacy systems can be a barrier for some organizations. Ethical Concerns: Issues like potential algorithmic bias and the need for continuous human oversight to prevent AI errors will require careful management. To discuss how Nelson Advisors can help your Healthcare AI company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

What is driving MedTech valuation multiples in Europe mid...

Nelson Advisors: Boutique European MedTech Investment Ban...

The Future of GLP-1 Pills for Weight Loss

Virtual Wards: what is the next evolution, why and when?

Electric Medicine attracting investment and driving strat...

Ambient Voice Technology predictions 2026